Results 51 to 60 of about 1,892 (131)
Cell Therapy for Periodontal, Soft‐Tissue, and Craniofacial Regeneration
Journal of Periodontal Research, EarlyView.The clinical translation of mesenchymal stem/stromal cells (MSCs) represents a major advancement in dentistry, especially for periodontal, soft‐tissue, and craniofacial regeneration. However, several challenges remain to be addressed, including the absence of standardised protocols, limited scalability, regulatory hurdles, a lack of well‐controlled ...
Kamal Mustafa +5 more
wiley +1 more source
Propelling Healthcare with Advanced Therapy Medicinal Products: A Policy Discussion
Biomedicine Hub, 2020 Recent advances in biomedicine are opening the door to new approaches, and treatment and prevention are being transformed by novel medicines based on genetic engineering, innovative cell-based therapies and tissue-engineered products, and combinations of
Denis Horgan +17 more
doaj +1 more source
MedComm, Volume 7, Issue 10, October 2026.• EV content maintains cellular homeostasis and is involved in several disease onset and progression. • miRNA export in EVs depends on: RNA‐binding proteins recognizing motif sequences and on epitranscriptomic modifications. • The disclosure of delivery mechanisms is crucial for developing personalized EV‐based therapeutic tools. ABSTRACT Extracellular
Sabrina Garbo +4 more
wiley +1 more source
MedComm, Volume 7, Issue 10, October 2026.Our study reveals a novel mechanism by which MSC‐derived EVs alleviate NaIO3‐induced dry AMD‐like pathology. MSC‐EVs deliver miR‐486‐3p into retinal cells to directly inhibit the ferroptosis‐promoting target gene Lcn2. Concurrently, downregulated Lcn2 restores intracellular Gpx4 expression, thereby suppressing ferroptosis and rescuing retinal ...
Zheng Li +6 more
wiley +1 more source
Frontiers in Cell and Developmental Biology, 2020 The introduction of advanced therapy medicinal products (ATMPs) to the global pharma market has been revolutionizing the pharmaceutical industry and has opened new routes for treating various types of cancers and incurable diseases.
Roya Ramezankhani +21 more
doaj +1 more source
International Endodontic Journal, Volume 59, Issue 10, Page 2122-2142, October 2026.ABSTRACT Aim Hypoxic preconditioning of cells holds promise for regenerative therapies, yet identifying effective and safe methods for clinical application remains challenging. We aimed to determine optimal hypoxia‐mimetic small molecules (SMs) that stabilize hypoxia‐inducible factor‐1α (HIF‐1α) and their dosages for hypoxic preconditioning in stem ...
Hong Wang +9 more
wiley +1 more source
Cell and Gene Therapies: European View on Challenges in Translation and How to Address Them
Frontiers in Medicine, 2018 Advanced therapy medicinal products (ATMPs), i.e., cell and gene therapy products, is a rapidly evolving field of therapeutic development. A significant proportion of the products are being developed by academia or small/medium-sized enterprises (SMEs ...
Cécile F. Rousseau +6 more
doaj +1 more source
RISK ASSESSMENT OF ADVANCED THERAPY MEDICINAL PRODUCTS
Безопасность и риск фармакотерапии, 2018 Advanced therapy medicinal products (ATMP) represent a heterogeneous group of medicinal products, combined with the need for special regulation of their circulation.
R. N. Alyautdin +5 more
doaj
Addressing Pressing Needs in the Development of Advanced Therapies
Frontiers in Bioengineering and Biotechnology, 2017 The commercial development of advanced therapy medicinal products (ATMPs) represents great opportunity for therapeutic innovation but is beset by many challenges for its developers. Although the ATMP field continues to progress at a rapid pace, evidenced
David Morrow +2 more
doaj +1 more source
Inquiry: The Journal of Health Care Organization, Provision, and FinancingAdvanced therapy medicinal products (ATMPs) are ground-breaking genetic and cell/tissue-based therapies with the potential to treat and even cure myriad health conditions.
N. Ferizović MSc +6 more
doaj +1 more source